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Abstract
Background: The present work aims at determining HCV genotypes in patients with chronic
HCV infection, in Gaza strip, Palestine. The most common risk factors for HCV transmission were
also evaluated in conjunction with the genotyping data.
Results: The study shows that there are only two major genotypes of HCV in Gaza Strip:
Genotype 1 (subtypes 1a and 1b) collectively contribute to 28.3% of the cases, and genotype 4
(subtypes 4a and 4c/d) collectively contribute to 64.1% of the cases. Mixed infection with the two
genotypes was also present among 7.6% of the cases. In this study a statistically significant
relationship was established between the distribution of these genotypes and the patients' living
place, traveling history, history of blood transfusion and history of surgical operations.
Conclusion: The present study is the first to link HCV genotyping in Gaza strip with its possible
roots of transmission. Traveling to endemic countries, especially Egypt; blood transfusion and
surgical operations are major roots of HCV infection in Gaza strip. The results indicate that
iatrogenic and nosocomial procedures may be responsible for the majority of HCV infections in
Gaza strip.
Background
Hepatitis C is caused by infection of liver cells with hepa-
titis C virus (HCV) leading to sever inflammation of the
liver [1]. Most HCV infections persist, leading to chronic
hepatitis, which can develop into chronic active hepatitis,
liver cirrhosis and hepatocellular carcinoma [2].
The number of people infected with HCV has recently
reached epidemic proportions and became a major global
health issue. Over 170 million are infected worldwide [3].
The latest published HCV prevalence among Palestinian
blood donors, in 2005, was 0.2% with an incidence rate
of 5.2 per 100,000 [4]. Egypt, the closest neighbor to Gaza
strip and its gateway to the world, has possibly the highest
HCV prevalence in the world. A recent study showed that
HCV antibody prevalence in a rural Egyptian area was
18.5%, reaching 45% in males over 40 years, and 30% in
females over 50 years [5]. Approximately 20% of Egyptian
blood donors are anti-HCV positive, and the strong
homogeneity of HCV subtypes found in Egypt (mostly 4a)
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suggests an epidemic spread of HCV [6]. Other med-east-
ern countries such as Saudi Arabia, Syria and Jordan have
HCV prevalence rates of 2.5%, 1% and 1.7% respectively
[7-9]. In Israel, the reported prevalence of HCV infection
is 0.5% [10].
HCV is known to have a marked genetic heterogeneity
with an estimated nucleotide substitution rate of between
1.44 × 10-3 and 1.92 × 10-3 substitutions per site per year
[11]. Accumulation of these nucleotide substitutions has
resulted in the evolution of at least six major HCV geno-
types (1–6) and more than 50 subtypes (designated by an
alphabetic letter) that differ by as much as 30%–50% of
their genome sequences [12]. Prevalence of the different
HCV genotypes varies according to the geographic region
[13,14].
There is evidence associating certain genotypes of HCV
with more sever hepatic pathology or quicker disease pro-
gression [13,15,16]. HCV genotype is a major predictive
factor of the treatment outcome, and hence has a strong
influence on the choice of treatment [17,18]. If taken in
conjunction with other factors important in therapy, HCV
genotyping will reduce the expenses for HCV patient's
treatment when the duration of the therapy is optimized,
and thus allowing a larger number of patients to be con-
sidered. This is especially important in a place like Gaza
strip that suffers from limited financial recourses. Cur-
rently, there is almost no available data about the most
prevalent HCV genotypes in the Palestinian authority ter-
ritories. Moreover, the clinical value of HCV genotyping
in HCV treatment is underestimated by Palestinian physi-
cians. A study conducted in 1998 showed that the most
common genotype found in Gaza strip is type 4 [19]. The
results of the study suggested that HCV root of transmis-
sion to Gaza strip is mainly from Egypt. This study how-
ever, was carried out on a small sample of a limited
population, mostly blood donors, of Gaza strip.
In this study, we determined the distribution of HCV gen-
otypes among chronically infected HCV patients in Gaza
strip. We also used the data obtained from HCV genotyp-
ing and the data collected by a questionnaire to evaluate
the possible role of some risk factors for HCV incidence as
well as to uncover possible origin of transmission of the
virus in Gaza strip.
Results
RT-PCR Amplification
Among the 100 samples tested by RT-PCR, 92 were found
positive and gave the characteristic 298 bps band on the
gel. Sensitivity of the test (≤50 copies/ml) was evaluated
by testing samples with various levels of viremia. Specifi-
city of the PCR test was confirmed by sequencing. The
quality of PCR reactions and the lack of contamination
were assessed by the inclusion of a negative (H2O) control
which didn't show any PCR amplification in all experi-
ments.
HCV genotypes and subtypes in Gaza Strip
Only two major genotypes of HCV in Gaza Strip were
detected (table 1): Genotype 1 (subtypes 1a and 1b), col-
lectively contributed to 28.3% of the cases (n = 26), and
genotype 4 (subtypes 4a and 4c/d), collectively contrib-
uted to 64.1% of the cases (n = 59). Mixed infection with
genotypes 1 and 4 was also detected among 7.6% of the
cases (n = 7).
Because of the small number of patients classified under
most of the detected subtypes, we collectively combined
genotype 1 and its subtype under the same category; gen-
otype 4 and its subtypes under a second category and the
mixed infections under a third.
Genotype and age of patient
The mean study population age was 47.55 ± 17.1 years.
No statistically significant difference was detected
between the mean age of the genotype groups. However,
it is noteworthy to mention that 71.4% of mixed genotype
infections are elder patients, over 60 years, compared to
15.4% for genotype 1 patients (P = 0.01, odds ratio =
13.75).
Genotype and place of living
The majority of the study population (63%) were from
the south of Gaza Strip and 34 (37%) were from the
north. The majority of southern patients were infected
with genotype 4 (72.4%) compared to (50.0%) of the
Northern patients (p = 0.035) (Table 2).
If we look at the distribution of genotype 4 alone, we find
that 71.2% of patients infected with this genotype are
located in the Southern part of Gaza Strip compared to
28.8% in the Northern part. This difference is statically
significant (P = 0.01; odds ratio = 3.29). On the other
Table 1: Frequencies of HCV genotypes in the 92 patients 
studied in Gaza Strip
Genotype N %
Genotype 1 and its subtypes 26 28.3
1a 17 18.5
1b 99 . 8
Genotype 4 and its subtypes 59 64.1
4a 40 43.5
4c/d 19 20.6
Mixed Genotypes (1+4) 77 . 6
Total 92 100Virology Journal 2009, 6:105 http://www.virologyj.com/content/6/1/105
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Table 2: distribution of HCV genotypes among different study categories
Genotype P-Value
141 + 4
Place of living South 11 42 5 0.035
North 15 17 2
Total 26 59 7
Traveling No None 12 22 1
Before Egypt 1 25 2 0.000
Others 32 2
Egypt & others 31 0
Total 72 8 4
After Egypt 10 0
Don't Know Egypt 4 7 1 0.742
Others 11 0
Egypt & others 11 1
Total 69 2
Blood Transfusion No None 15 35 2
Before Gaza 10 11 4 0.017
Egypt 01 3 1
Jordan 10 0
Total 11 24 5
Surgery No None 12 33 3
Before Local 8 7 2 0.014
Egypt 01 3 0
Others 01 1
Local & others 21 0
Egypt & others 11 1
Total 11 23 4
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hand, type 1 is almost equally distributed among South-
ern patients (42.3%) and Northern patients (57.7%).
Genotype and traveling history
Patients with a history of traveling abroad (n = 57) are
almost twice those with no traveling history (n = 35).
Thirty nine patients (68.4%) traveled before being
infected (Table 2). Only one patient traveled after he was
infected, while 17 patients (29.8%) couldn't recall if they
traveled before or after the infection.
If we consider only patients with a traveling history before
infection, we find that 71.8% have traveled to Egypt;
17.9% to other countries, like Jordan, Saudi Arabia and
10.2% to Egypt and others. Among those who traveled to
Egypt before infection, significantly more patients 89.3%
are infected with type 4 and its subtypes compared to the
other genotypes (P value = 0.000).
Genotype and history of blood transfusion
All of the 40 patients with a history of blood transfusion
(43.5%), got their blood transfusion before being infected
with HCV. Five out of 7 patients with mixed genotypes
(71.4%) have a history of blood transfusion (table 2).
A significant relation could be established between the
genotypes and place of transfusion (P value = 0.017).
Thirteen out of 14 patients (92.9%) who had a transfu-
sion in Egypt are infected with type 4. No preference how-
ever was seen between genotypes 1 (40%) or genotypes 4
(44%) for patients who had a transfusion in Gaza Strip (n
= 25). Only one patient was transfused in Jordan and he
is infected by genotype 1.
Genotype and history of surgical operations
A total of 45 patients had a history of medical surgery
(48.9%). Most of them (86.7%) were operated before
HCV infection and only 6.7% were infected after surgery
(Table 2). A significant relation could be established
between HCV genotype and place of surgery (P-value =
0.014). All patients who had their surgeries in Egypt for
example (n = 13) have type 4 infection, while slightly
more patients with type 1 (47.1%) than type 4 (41.2%)
had their surgeries in Gaza.
Genotype and serum ALT level
A significant relation could be established between the
number of patients with ALT values above or below 40 IU
mL-1 (the normal upper limit) and the genotype of the
patient (P-value = 0.002). For example, 73.1% of the
patients infected with type 1 had ALT values above 40 IU
mL-1. On the other hand 66% of type 4 patients, and
71.4% of mixed-genotypes patients had ALT values lower
than 40 IU mL-1 (table 2).
Discussion
HCV genotyping may shed light on its evolution, source
of outbreaks, and risk factors. It may be used to identify
the source of infection in cases of patient-to-patient trans-
mission and is also useful in the study of other modes
such as vertical (mother to baby), sexual transmission and
needle stick injury [20-22].
Results of this study indicate that there are only two major
genotypes of HCV among chronic carriers in Gaza Strip:
Genotype 1 and its subtypes 1a and 1b, and genotype 4
and its subtypes 4a and 4c/d. Mixed infection with the two
genotypes was also detected. HCV genotype 4 and its sub-
types are the predominant genotypes in Gaza strip
(64.1%).
Genotypes 1 and 4 were previously reported to be more
pathogenic and considered more difficult to treat. The rate
of progression to chronicity after acute exposure to HCV is
significantly higher in patients exposed to HCV genotypes
1b and 4 infections than in patients exposed to other gen-
otypes [14,23]. Patients with HCV genotype 1a or 1b have
more severe liver disease and lower rates of response to
interferon therapy than patients with HCV genotype 2a or
2b [24]. Recent clinical trials show that success of HCV
genotype 4 therapy is dependent on the applied protocol.
This genotype doesn't seem difficult to treat when
Pegylated IFN and ribavirin combination therapy is
applied, as the response to treatment may be at an inter-
Egypt 01 0
Total 21 0
Don't Know Local 12 0
ALT level ≤ 40 IU  7 39 5 0.002
> 40 IU  19 20 2
Total 26 59 7
Table 2: distribution of HCV genotypes among different study categories (Continued)Virology Journal 2009, 6:105 http://www.virologyj.com/content/6/1/105
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mediate level compared with genotype 1 and genotypes 2
or 3 [25]. Moreover patients infected with type 1 and 4
had a higher viral load than patients infected with other
genotypes [26].
The two major HCV genotypes (1 and 4) were found to be
significantly distributed among patients from the south
and north of Gaza strip (P-value = 0.035). Genotype 4 and
its subtypes are concentrated in the south of Gaza strip
(71.2%), while genotype 1 is slightly more represented in
the north (57.7%) than in the south (42.3%).
It is well documented that genotype 4 and its subtypes
especially 4a are the predominant genotypes in Egypt, the
southern border of Gaza strip and its only gateway to
other parts of the world. Many Gaza residents, especially
from the south, have historical relationships with the
Egyptian people as members of many families were
divided between Gaza and Egypt, while keeping strong
social links with frequent visits from both sides. On the
other hand, Israel with the most predominant genotype 1
and its subtypes borders Gaza strip from the north. More-
over, the Egyptians ruled Gaza strip in the period between
1948 and 1967 and Israel occupied Gaza at 1967 and con-
trolled the Palestinian lives until the establishment of the
Palestinian National Authority. Based on this informa-
tion, the genotypes distribution in the south and north of
Gaza and each of Egypt and Israel may be correlated.
Traveling to endemic areas is associated with increased
risk of HCV infection [27]. Our results show that HCV
patients who have traveled to a foreign country (62.0%)
are almost twice those who haven't (38.0%). The majority
of patients with a traveling history (68.4%) traveled
before they were infected. Only one patient reported that
he traveled after he was infected, and 17 patients (29.8%)
did not know if they traveled before or after the infection.
Egypt was the most frequently visited country (72%of
those with traveling history). Egypt shows the highest
HCV prevalence in the world [14,28]. The majority of
patients who traveled to Egypt before infection (89.3%)
have genotype 4.
Surgery is another risk factor for nosocomial HCV trans-
mission in a health care setting [29,30]. Our results show
that almost half of the patients participating in the study
(48.9%) had a surgical operation, of which 86.7% had
their surgery before HCV infection. Furthermore, there
was a significant correlation between the place of surgery
and HCV genotype (P value = 0.014). All patients who
had their surgeries in Egypt had genotype 4. This suggests
that those patients might have got infected during surgery.
On the other hand, slightly more patients with genotype
1 (47.1%) than genotype 4 (41.2%) had their surgeries in
Gaza.
A significant relation was established between the number
of patients with ALT values above or below 40 IU mL-1
(the normal upper limit) and genotype of the patient (P-
value = 0.002). Most of patients infected with genotype 1
(73.1%) have ALT values above 40 IU mL-1. On the other
hand most of patients with genotype 4 (66%), and mixed
genotypes (71.4%) had ALT values lower than 40 IU mL-
1. These results confirmed earlier reports showing that
patients infected with genotype 1 are more susceptible to
liver complications, hepatocellular carcinoma, and
decompensate liver disease, than those infected with gen-
otype 4 [24].
During blood transfusion, there is high risk of getting
infected with HCV, especially when laboratory screening
techniques are absent or fail to detect HCV infection in a
fraction of blood donations. This makes HCV responsible
for about 90%–95% of transfusion-associated hepatitis
cases [31,32].
Our results show that all patients with a history of blood
transfusion (43.5%) got their blood transfusion before
being infected with HCV. Blood transfusion gives a higher
chance for infection with mixed genotypes than with
either type 1 or type 4 alone. Five out of 7 patients with
mixed genotypes (71.4%) have a history of blood transfu-
sion.
A significant relation was established between HCV geno-
types and the place of transfusion (P-value = 0.017). This
relation is clear in the case of Egypt, as 13 out of 14
patients (92.9%) who had a transfusion in Egypt are
infected by the genotype 4, the dominant genotypes in
Egypt. No preference however could be seen between gen-
otypes 1 (40%) or 4 (44%) for patients who had a trans-
fusion in Gaza Strip. Double infection is present in 5 of 40
patients (12.5%) who had received blood. Those patients
were exposed to repeated blood transfusion or infected by
another rout of HCV transmission. Like in surgery, these
data are supported by sequence comparison (not shown).
One patient who had surgery in Egypt was infected by
genotype 1a, a rare genotype in Egypt. However, this
patient had previously a blood transfusion in Gaza, from
which he might have gotten his infection. Screening for
HCV in blood banks is a mandatory procedure in Gaza
and partly in Egypt and a high risk of HCV infection
among egyptian blood donors was previously reported
[33].
Conclusion
Our results show that there are only two major circulating
genotypes of HCV in Gaza Strip: Genotype 1 (subtypes 1aVirology Journal 2009, 6:105 http://www.virologyj.com/content/6/1/105
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and 1b); and genotype 4 (subtypes 4a and 4c/d). Mixed
infection with the two genotypes was also seen. The
results also show that traveling to endemic countries (par-
ticularly Egypt), blood transfusion and surgical opera-
tions are the major roots of HCV infection in Gaza strip.
Therefore, iatrogenic and nosocomial procedures may be
responsible for the majority of HCV infections in Gaza
strip although other roots of transmission must be present
as 14 patients (15.2%) were excluded from any of these
categories.
Materials and methods
Patients and Samples collection
The present study is a descriptive study for genotyping
HCV isolates from Gaza strip. The study population was
chosen based on availability from patients attending the
two major hepatology departments in a six-month period
(100 patients). Male and female subjects who are chroni-
cally infected with HCV (based on previous diagnosis
either by ELISA or RT-PCR) were included in the study.
Only Patients positive for HCV RNA were included in
sequencing and genotype determination (91 patients).
Peripheral blood samples were collected, in plain tubes
from 55 patients attending the European Gaza hospital
(south of Gaza strip), and 45 patients attending Al-Shiffa
hospital and Al Remal clinic (north of Gaza strip). Fifteen of
these samples were collected from dialysis patients. Serum
samples were prepared within no more than 4 hours after
withdrawal and were immediately stored in sterile DNase-
and RNase-free, tightly caped tubes, at -70°C.
The procedures of the study were approved by the local
Helsinki committee according to the World Medical Asso-
ciation Declaration of Helsinki [34] and a written consent
was obtained from each patient. A close-ended, dichoto-
mous and multiple-choice based questionnaire was
designed and completed based on patients' interview.
Biochemistry
ALT was analyzed for all samples using Alcyon auto-ana-
lyser and commercially available kit (DiaSys Diagnostic
System GmbH, Germany) according to the manufacturer
instructions. The normal range for ALT was considered
from 0 to 40 IU mL-1.
Primers sequences
The forward primer: CCCTGTGAGGAACTWCTGTCT-
TCACGC (W  is A or T) and the reverse primer: GGT-
GCACGGTCTACGAGACCT were designed to specifically
bind the region between -299 and -1 of HCV genome
5'UTR respectively [35]. This region is highly conserved
among the different genotypes. Sequence degeneracy was
included to allow annealing to the various genotypes.
Viral RNA Extraction and HCV RT-PCR amplification
Viral RNA was extracted from 140 μl serum samples using
the QIAamp viral RNA Extraction kit according to the
manufactures recommendations (Qiagen, Germany).
Both cDNA synthesis and PCR amplification of target
sequences were performed in a single tube using the QIA-
GEN one step RT-PCR kit (Qiagen, Germany). The reac-
tions were carried out in 25 μl reaction volumes using 10
μl RNA in the presence of 0.6 μM of each primer, 400 μM
of each dNTP and 5 units RNase inhibitor. The reaction
cycling conditions were: one cycle at 50°C for 30 minutes
and one cycle at 95°C for 15 minutes followed by 40
cycles of 95°C for one minute, 55°C for one minute and
72°C for one minute. Finally the reactions were allowed
to complete at 72°C for 10 minutes and held at 4°C. The
products were analyzed on 2% agarose gel and stained
with ethedium bromide. The PCR products were purified
from the gel using the Qiaquick Gel Extraction Kit accord-
ing to the manufacture instructions (Qiagen, Germany).
HCV genotyping and sequence analysis
Although a variety of methods have been used for HCV
genotyping, sequencing of an informative region of its
genome (the 5'UTR) remains the golden standard. The
5'UTR is highly conserved, and therefore is very suitable
for both RT-PCR detection and genotyping of HCV.
Sequencing and genotype determination of the purified
PCR products were conducted by Hy-labs (Park Tamar,
Rehovot), using the Big Dye Terminator Cycle Sequencing
kit and the analysis software for downstream analysis of
sequences (ABI, USA).
Polygenetic analyses were performed on the 5'-UTR of
HCV (175 bp, position 11–185 gb|DQ418782.1|. Pair-
wise analysis was performed using multiple sequence
alignment. The ClustalW program [36] was used to deter-
mine the genetic distance; divergence of nucleotide substi-
tutions per 100 nucleotide sites and neighbor joining
slanted phylogram tree analysis. Comparison between
means of nucleotide variability was carried out using Stu-
dent's t-test for independent samples. Results were consid-
ered significant at P < 0.05.
Statistical analysis
The questioner results were transformed into numerical
scoring system, and the statistical analysis was carried out
(by SPSS and Epi-info), using frequencies and cross tabu-
lation between dependant and independent variables.
Chi square test and T test were used and P-values of < 0.05
were considered statistically significant.
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